EGFR and neoplasm: Also included was one patient with a non-exon 20 insertion who was previously treated with several lines of therapy and whose tumor harbored EGFR E19del/T790M alterations and the hotspot PIK3CA mutation R88Q at baseline (after progression on multiple lines of chemotherapy, including erlotinib, capmatinib, afatinib, osimertinib, and necitumumab).